Our Staff

Bashar Al-Nakhala
Bashar Al-Nakhala
Chief Operating Officer
Bashar joined the ALS Therapy Development Institute in 2005 initially as the Director of Bioinformatics. Today, as Vice President of Information Technology, he oversees the organization’s technical infrastructure and internal technology systems. Bashar has over 22 years of experience in software development, information systems, and managing cross-functional teams. Prior to joining the Institute, Bashar was the Director of Development at IMN INC, a leading e-marking global company. Bashar has also held roles as a technology advisor and consultant to various start-ups, large companies such as EMD Serono, and non-profits such as Youth Build USA, and Urban League of Eastern Massachusetts. Earlier in his career, Bashar spent several years working at Microsoft and Amazon.com, where he was involved in developing some of their earlier products. Bashar holds an MBA from Northeastern University, and a Software Engineering and Computer Science degrees from the University of Washington and Wentworth Institute of Technology respectively.
Katherine Asquith
Katherine Asquith
Data and Stewardship Coordinator
Kaycee joined ALS Therapy Development Institute in 2018. In her role as Data & Stewardship Coordinator, Kaycee focuses on supporting the lead management team and donor relations. Originally from Rhode Island, she stayed local for college attending Bryant University where she played one year of Division I Lacrosse and majored in marketing. Starting internships in high school in many different areas, including senator campaigns and marketing for the Red Sox, Kaycee came to ALS TDI looking for a role in which she would be contributing to a greater cause. Recently, Kaycee just starred in a commercial for a local waste disposal company!

“There is nothing in the world so irresistibly contagious as laughter and good humor." - Charles Dickens
Gabrielle Bellitti, M.S.
Gabrielle Bellitti, M.S.
Community Outreach & Engagement Specialist
Gabrielle Bellitti joined the ALS Therapy Development Institute in 2019 as the Outreach & Community Engagement Specialist. In her role she will build broad based awareness and sustained support for ALS TDI research programs to insure that all outreach programs and messages align with our mission and scientific standards.

Prior to joining ALS TDI she served as the Community Outreach Specialist for California Cryobank; the world’s largest reproductive, tissue, storage and stem cell bank in the country. After spending 5 years committed to helping to create families, Gabby enthusiastically joined the ALS TDI community to help bring her passion to spreading awareness and advocacy in the fight against ALS. Gabby graduated with a Master’s degree from Capella University and is a current PhD candidate in Psychology.

A native of Cambridge MA, Gabby was lucky enough to have lived in other states and countries but has made her way back home. She enjoys spending time with her two sons, hiking and being outdoors when the weather permits. She is also a die-hard New England Patriot's fan! She lives by the quote, "There is no such thing as a perfect parent. So just be a real one." (Sue Atkins).
Alex Calo
Alex Calo
Associate Scientist II
Alessandro Calo joined the ALS Therapy Development Institute in 2015 right after receiving his Bachelor's of Science in Biology from Northeastern University. Despite his recent graduation, he has experience working in a breadth of laboratory settings including the Northeastern University, Brigham and Women’s, and Pfizer.
As a member of the Translational Research group, his work is focused in the Institute’s Precision Medicine Program. He is responsible for the program’s genetic analysis along with the development and implementation of automated methodology using our Integrated Robotic System. Alessandro was drawn to the Institute by the ideology of the non-profit biotech company, driven by passion rather than profit. Though, the task at hand became more personal when his close childhood friend’s father was diagnosed with ALS and passed in November 2015.
Alessandro grew up in Golden, Colorado. He enjoys anything outdoors whether it be hiking, skiing, or relaxing on the beach. He is often found pondering strange plants and animals.
“When I was a boy and I would see scary things in the news, my mother would say to me, “Look for the helpers. You will always find people who are helping.”
-Mr. Rogers
Isarelis Carrion
Isarelis Carrion
Histology Technician
Isarelis (Isa) J. Carrion joined the ALS Therapy Development Institute in September, 2007 and is part of the Histology team. This team specializes in processing frozen tissues to provide scientists with tissue section slides, so they can used them as secondary screening assays. Isa loves to work at the Institute because we always put the patients first and our mission is simple - to find a cure for ALS as soon as possible. Isa earned her BS in Biology at UMass Boston. She lives with her three beautiful boys in Cambridge, MA.
Nicole Chen
Nicole Chen
Associate Scientist I
Xiaoying Chen (Nicole) joined the ALS Therapy Development Institute as part of the Translational Research group in 2018. She brings her passion for cell and molecular biology to work on assay development and drug screening with patient-derived cell lines. Four years ago, Nicole left Shanghai, China to Boston for University. She is a recent graduate from Northeastern University with a Bachelor Degree with honors of Science in Biology and minors in Math and Business. Besides education, she did a direct study on gene therapy with her Professor Ke Zhang for three years and had one publication as a co-author; also, she did a Co-Op at Neon Therapeutics in Molecular Immunology group. Coming with research experience of immunology, and cell and molecular biology, she wants to contribute to curing ALS as part of the team of ALS TDI. Besides research, she enjoyed cooking, playing Guzheng (a traditional Chinese instrument) and sports including sailing, swimming, hiking, and basketball.
Dileep Dadlani
Dileep Dadlani
Director of Development - Southeast Region
Dileep joined the ALS Therapy Development Institute in March 2019 with the ultimate goal of helping fund ALS TDI's mission until an effective treatment and cure is found for ALS. Dileep supports ALS TDI by cultivating relationships, foundations, and special events.

Originally from Ft. Lauderdale, Florida, Dileep moved to Raleigh, North Carolina in 2008, where he held development positions in the disease based non-profit sector. Dileep spent eight years working in the ALS community after losing his best friend to ALS. When not trying to save the world, Dileep enjoys spending time with his wife, two small dogs, competing in triathlons, cycling, and volunteering for just about everything.

Dileep lives by the familiar quote, "Be the change you wish to see in the world," and it continues to motivate him as a change agent every day.
Kyle Denton, Ph.D.
Kyle Denton, Ph.D.
Scientist II
Dr. Kyle Denton joined the ALS Therapy Development Institute in 2016. He is currently working on establishing high-throughput methods for generating neural subtypes from patient induced pluripotent stem cells to use in phenotype discovery and drug screening studies. Kyle joined the Institute because of his interest in neurodegenerative research and the opportunity to work with the resources that the Precision Medicine Program provides. He came to the Institute after a postdoctoral position in Dr. Jennifer Lippincott-Schwartz’s lab at the National Institutes of Health. Kyle received his Ph.D. from the University of Connecticut Health Center in Biomedical Sciences, with a concentration in neuroscience. Prior to that, he received his B.A. and M.A. from Clark University in Biochemistry and Molecular Biology in 2010 and 2011, respectively. In his free time, Kyle enjoys cycling and hiking.
Emily Dhondt
Emily Dhondt
Digital Marketing Manager
Emily joined the ALS Therapy Development Institute in March 2017 after moving to Boston. As the Digital Marketing Manager, she spends her days sharing the stories of people living with ALS and the mission of ALS TDI. Emily is from Tampa, FL and graduated from the University of Florida with a Bachelor of Science in Advertising in 2014. In her free time she enjoys traveling, eating, improv, running, and spending time with friends and family.

“Embrace the glorious mess that you are” - Elizabeth Gilbert
Ben Engle
Ben Engle
Director of Event and Program Production
Ben Engle joined the ALS Therapy Development Institute in 2012. As a Development Director, Ben raises money and awareness to support the vital research being done at the Institute. He feels honored to have the privilege of working alongside the many intelligent and dedicated people at the Institute who are 100% committed to finding a cure for ALS. Prior to joining the team, Ben spent several years working as a professional chef. He graduated from Northeastern University in 2010 with a bachelor's degree in Political Science and a minor in International Affairs. Ben has enjoyed living in Boston since 2005 and currently resides in Dorchester with his wife, Molly.
“…plans are useless, but planning is indispensable.” - Dwight D. Eisenhower
Caitlin Faulds
Caitlin Faulds
Science and Grant Writer
Caitlin Faulds joined the ALS Therapy Development Institute in 2017. She was struck by how committed the team at ALS TDI is to progressing research and is proud to be part of such a unique and diverse group. As part of the finance team she supports donor communication and makes sure that all donations get where they need to go. Before joining ALS TDI, Caitlin studied social anthropology at the University of St Andrews, Scotland. Her experience with fundraising began here when she led a student charity trek to Mt Kilimanjaro for Worldwide Cancer Research. After graduating, she moved to the woods of Western Massachusetts to join an AmeriCorps group doing environmental education and trail work in parks around the state. In her free time she enjoys hiking, playing violin, and traveling and camping when she can.

"Of all the paths you take in life, make sure a few of them are dirt." - John Muir
Matt Ferola
Matt Ferola
Senior Animal Technician I
Matt Ferola joined the ALS Therapy Development Institute in 2003. Having lost his grandmother's cousin to ALS, Matt has been a dedicated member of the animal care team here at the institute. His primary goal is to maintain the animal facility and provide clean and healthy environments for all of the mice involved in research studies. Matt grew up in Somerville, Massachusetts and pursued a certificate in graphic communications before joining the research staff at the Institute.
Anna Gill
Anna Gill
Associate Scientist I
Anna Gill joined the ALS Therapy Development Institute in 2015. She started as a part-time research intern while completing her Bachelor's degree, and transitioned to a full-time scientist on the In-vivo team starting in 2018. Her current focus is studying the biological mechanisms of C9ORF72-ALS pathology using newly-developed cell-based models and assays. Anna graduated cum laude from Emmanuel College with a B.S. in Biology concentrating in Health Sciences, and intends to pursue a graduate degree. As a full time student and part time intern, she wrote and defended an undergraduate thesis titled "Investigating cellular effects of neurodegeneration-associated peptides in C9ORF72 ALS" based on research done at ALS-TDI. Her parents Alan and Cindy Gill have worked at ALS TDI for over 10 years, which gave her a unique opportunity to watch the institute grow from the ground up. She continues to be humbled and inspired by those living with ALS, their families, and her coworkers, who give everything they have to make this lab a life-changing powerhouse to grow in.

"Look up at the stars and not down at your feet." – Stephen Hawking
Cindy Gill
Cindy Gill
Senior Associate Scientist
Cindy Gill joined ALS Therapy Development Institute in 2008. Cindy received an undergraduate degree in Biology from Simmons College and spent 15 years in Research at biotechnology companies, including 9 years at Biogen. She was involved primarily in the discovery and testing of Immunology-based therapeutics, and has an extensive background in monoclonal antibody production and the in-vitro/in-vivo characterization of potential drugs. She took a break from biotech to nearly complete a second degree from Simmons in Nursing and to be home with her two children, Anna and Joe. At the Institute, Cindy works in the Pharmacology group to help evaluate in-vivo drug effects in the G93A model.
Alan Gill, Ph.D.
Alan Gill, Ph.D.
Vice President of Research
Dr. Alan Gill joined the ALS Therapy Development Institute in 2007. He is an experienced pharmacologist/physiologist with a thorough understanding of practical investigation in complex in vivo animal systems. He came to the Institute after a one-year immersion in Huntington's disease drug discovery as the Director and Head of Pharmacology at EnVivo Pharmaceuticals, a biotechnology company concentrating on neurodegenerative diseases. Prior to EnVivo he worked for 13 years in Biogen and Biogen Idec's drug discovery research division where he instituted Biogen's Pharmacology Department. These efforts led to drug candidates that were the basis for collaboration with Merck and Co. for their clinical development, and to small molecule and protein potential therapeutics selected for development by Biogen Idec itself. Prior to working for Biogen, Alan worked for 12 years with Johnson & Johnson's worldwide drug discovery research division. He received his Ph.D. in Pharmacology from the M.S. Hershey Medical Center of the Pennsylvania State University, and his Master's degree in Physiology and Bachelor's degree in Biology from the University of San Francisco.
Alicia Grossi
Alicia Grossi
Director of Donor Communications & Stewardship
Alicia Grossi joined the ALS Therapy Development institute in 2006. Her grandfather missed a lifetime when he died of ALS at age 51. She wants to change that for people facing ALS today. Alicia graduated from Quinnipiac University with a degree in Advertising and began fundraising, event planning and marketing as an intern for the Tri-State Trek. In her role as Director of Donor Communications & Stewardship, Alicia manages comprehensive donor relations and our stewardship program, interacting with 35,000 annual donors. She has diverse experience in donor development, stewardship, marketing/communications and fundraising events.
“It is the enduring pursuit of a goal, not the fleeting glory of the finish line, that shapes the lasting victories within us.” ~ unknown
Carol Hamilton
Carol Hamilton
Senior Director of Development
Carol Hamilton joined ALS Therapy Development Institute in 2005. After a friend’s brother passed away of ALS, she joined first as a volunteer consultant, working on Capitol Hill to increase our federal funding. Carol worked closely with Congressional leaders, the Department of Defense, and the Department of Veterans Affairs to secure over $6M in contracts for the Institute. As Senior Director of Development, Carol works with foundations and donors to accelerate our work. Prior to joining ALS Therapy Development Institute, Carol was an executive at Saks Fifth Avenue, and ran a small company of her own. Carol studied at Oxford University, and graduated from the Georgetown University School of Business. She lives in Sherborn, and is the proud mother of two incredible young women.
“If you stand for nothing, Burr, what will you fall for?” ~Lin Manuel Miranda
Terri Handler
Terri Handler
Development Director
Terri Handler joined the ALS Therapy Development Institute in 2011, 7 months after she lost her brother to ALS. As a Development Director, Her job, along with a dedicated team, requires securing the urgent funding needed to move our research ahead as fast as possible. Her journey began in 2007 when she witnessed this disease firsthand but her work continues today for all the current ALS families to stop the pain and suffering and see an end to ALS. Terri’s brother is never far from her mind and she remembers him always saying his life was great but just too short.
"You can’t have a better tomorrow if you are always thinking about yesterday" ~ Author Unknown
Theo Hatzipetros, Ph.D
Theo Hatzipetros, Ph.D
Director of Pharmacology
Dr. Theo Hatzipetros joined the ALS Therapy Development Institute in 2011. He is an in vivo pharmacologist who specializes in the field of neurodegeneration. Prior to joining the Institute, Theo worked on drug discovery for the treatment of Parkinson's Disease at FoldRx Pharmaceuticals. At the ALS Therapy Development Institute, Theo's efforts are focused on the development of novel animal models of ALS and in evaluating therapeutic strategies for the treatment of the disease. Theo, originally from Cyprus, received his doctorate in pharmacology from Boston University School of Medicine for his thesis work on the neurotoxic effects of the psychostimulant methamphetamine.
Josh Kidd
Josh Kidd
Research Associate III
Joshua D. Kidd joined the ALS Therapy Development Institute in 2004. As a Research Associate, his job primarily involves studying the behavioral effects of different treatments in the SOD1-G93A Mouse model. Before coming to the Institute, Josh attended Minuteman Vocational Technical High School in Lexington, MA, where he earned a certificate in Graphic Design. Josh's family history with Huntington's Disease has given him a unique perspective and drives his desire to be a part of the effort to treat and cure devastating neurological diseases such as ALS. Since working at the Institute, he has earned his ALAT certification and is currently working towards a bachelor’s degree in biology at Northeastern University in Boston. Other than science, Josh is an avid animal lover and enjoys all things music and art. He currently calls Somerville his home.
Haley Knight
Haley Knight
Associate Scientist II
Haley Knight joined the ALS Therapy Development Institute in 2017 and began working in the Precision Medicine Program. She is responsible for maintaining patient samples and patient-derived cell lines. After she received her Bachelor’s Degree of Arts, in Neuroscience/Pre-med, from Wheaton College (MA), Haley began working at ALS TDI due to her passion for the medical field and desire to work in a focused and dedicated research environment. She has a broad professional background working in labs focused in biochemistry, psychology, and neurology. Born and raised in Pawtucket, Rhode Island, she enjoys film, tennis, and traveling.

“I am seeking, I am striving, I am in it with all my heart.” – Van Gogh
Megan Kosciak
Megan Kosciak
Events and Programs Manager
Megan Kosciak joined the ALS Therapy Development Institute in 2017. She has joined the development team as Development Coordinator after completing the Tri-State Trek Internship in 2016. She loved the hope and inspiring power that the Trek demonstrated and wanted to work for the worthy cause that the ALS Therapy Development Institute proved to be. Megan graduated from Curry College in 2017 with a degree in Communication and has a personal background in professional technical theatre. A favorite quote of Megan's that lives in her office is, "Live fully. Challenge yourself. Be kind and generous. Inspire someone. Be grateful. Take the road less traveled. It’s never too late."
Meghan Lawlor
Meghan Lawlor
Senior Director of Marketing and Communications
Meghan Lawlor joined the ALS Therapy Development Institute in 2019. As Senior Director of Marketing and Communications, Meghan works to ensure that we effectively articulate ALS TDI’s mission and work to the community that supports us. Meghan is honored to be a part of the dedicated team at ALS TDI and is inspired by the relentless spirit of the ALS community. Prior to joining ALS TDI, Meghan developed her diverse marketing and communications experience by working across a broad range of industries including non-profit, health, technology, and advertising.

Meghan graduated from Bentley University in 2006 with a bachelor’s degree in Marketing and a minor in Information Design & Corporate Communication. In her free time she enjoys traveling and spending time outdoors.

"What you risk reveals what you value." Jeanette Winterson
Beth Levine
Beth Levine
Senior Associate Scientist, Project Management
Beth Levine joined the ALS Therapy Development Institute in 2007. Beth brings 20 years of pharmaceutical and biotechnology experience to ALS Therapy Development Institute. As part of the Project Management team, it is her job to make sure projects run at maximum efficiency. She is also a member of the In Vivo Research group in which she is currently focused on studying the C9orf72 mutation. Beth is motivated everyday by the Institute’s unique approach to research based on one question – does this path lead us closer to a treatment or cure for ALS? Beth participates in many ALS fundraising events alongside people with ALS and their families and friends including riding in the Tri-State Trek and running in The Race for Research.
Matvey Lukashev
, Ph.D.
Matvey Lukashev , Ph.D.
Senior Director of Translational Research
Dr. Lukashev joined the ALS Therapy Development Institute in 2013 with over 20 years of postgraduate research experience and 14 years of biotechnology industry experience. He has supported and led therapeutic discovery and development programs across all stages of drug development in therapeutic areas of neurology, oncology, immunology and fibrosis. His leadership of the research effort supporting clinical development of Tecfidera, an oral small molecule therapeutic recently approved by the FDA for treatment of multiple sclerosis was recognized by an Outstanding Scientific Achievement Award from Biogen Idec, Inc. Dr. Lukashev received a Ph.D. from the Russian Academy of Medical Sciences, and postdoctoral training at Johns Hopkins and University of California, San Francisco.
Emer Martin
Emer Martin
Communications and Development Specialist
Emer Martin joined the ALS Therapy Development Institute in 2016. In her role as Communications and Development Specialist, Emer works to support the community with their local events and helps to produce community and donor communications in an effort to secure the vital funding required to continue the research here at ALS TDI. She is inspired by her colleagues across the team who demonstrate their commitment to putting an end to ALS every day. Previously, Emer has held roles in communications and HR. She is a graduate of Dublin City University and holds a Master’s degree in Science Communication. In her free time, Emer enjoys baking, exploring and crocheting.
Carlos Maya
Carlos Maya
Animal Technician I
Carlos joined the ALS Therapy Development Institute in 2005. Carlos is an animal technician on the science team. He has worked with animals since he was a young boy growing up on a farm in Colombia. His father was a veterinarian and taught Carlos how to care for the diverse animals on their farm. Carlos moved to the United States is 1991 and resides in Chelsea, MA, with his wife Juliana, and their children.
Eliza McDonough
Eliza McDonough
Events Manager
Eliza McDonough joined the ALS Therapy Development Institute in 2019. As the Events Development Manager, Eliza supports the events team in planning, managing, and executing signature and other fundraising events for ALS TDI. Throughout her life, Eliza has volunteered with multiple nonprofit organizations focused on human services and is honored to be a part of the ALS TDI team.

Previously, Eliza worked as a private event and fundraiser specialist with Paint Nite, organizing and planning hundreds of painting events per year throughout the entire United States and Canada. She was also high school English teacher, working with children with special needs from grades 9-12.

Eliza graduated from Saint Michael's College in Vermont with a Bachelor’s degree in English Literature and Education. In her free time, she enjoys baking, going to the beach, and taking her dog, Bernie, for hikes.

"Unless someone like you cares a whole awful lot, nothing is going to get better. It's not." -Dr. Seuss, The Lorax
Jennifer McErlain
Jennifer McErlain
Director of Development - Western Region
Jennifer McErlain joined the ALS Therapy Development Institute in 2015 as a Development Manager. Her passion for helping individuals affected by ALS and their families began during her time working with the Muscular Dystrophy Association where she served as Health Care Services Coordinator. Prior to MDA, Jennifer worked with a nonprofit to assist people living in affordable housing communities achieve greater self-sufficiency through education and social services.
In her free time, she enjoys spending time outdoors, discovering new music, and eating other people's cooking. She resides in Northern Oakland, CA, with her husband, two children, and her cat. Jennifer is proud and honored to be part of the Development team at the Institute and fund cutting-edge research to end ALS.
"Character is how you treat those who can do nothing for you." ~ Johann Wolfgang von Goethe
Maeve McNally
Maeve McNally
Senior Director of Clinical Operations & Executive Administrator to the CEO
Maeve joined the ALS Therapy Development Institute in January 2012. She is originally from Ireland and holds a Degree in Business Administration. She previously worked as a project manager at Millennium Pharmaceuticals. Prior to this, she was employed at the Harvard Institute for International Development, following her role as an Administrator for a medical Non-Government Organization based in East Africa that responded to complex emergencies. In her spare time, Maeve enjoys hiking, tennis, horseback riding and cooking. She lives with her family and their dog, named Bono in Cambridge.
As Director of Clinical Operations she is a member of the senior leadership team reporting directly to the CEO to deliver high quality patient outcomes and an exceptional patient experience while also focusing on efficiency and reducing costs. She directs, coordinates and monitors the operational, financial and personnel performance of the clinical department, and develops and implements department policies, initiatives and objectives to assist in achieving the Institute's vision and strategic goal of finding a therapeutic for ALS.
Andy Moreno
Andy Moreno
Research Associate II
Andy Moreno joined the ALS Therapy Development Institute in 2002. At the Institute Andy is responsible for executing experimental drug studies in animal models of ALS. The fight of ALS patients and the dedication of their friends and families is what inspires Andy on a daily basis. Before joining the ALS Therapy Development Institute, Mr. Moreno worked for Harvard University Medical School. Andy attended the famous Cambridge Rindge and Latin School, the alma mater of Ben Affleck and Matt Damon, and thereafter Boston College. Andy, with his beautiful family, reside in Arlington, MA and they like to hike together in their free time.
Kaly Mueller
Kaly Mueller
Associate Scientist III
Kaly Mueller joined the ALS Therapy Development Institute in 2018 after spending four years at Massachusetts General Hospital, where she researched the potential mechanisms behind neuronal death in Huntington's disease and ALS. As a member of the in vivo team, her current focus is providing detailed and accurate phenotypes for novel mouse models in hopes of incorporating them into future pre-clinical drug studies. She draws inspiration from the strength of ALS patients and their families, as well as the passion her coworkers display on a daily basis. Kaly graduated with a BS in Physiology from Marquette University in 2012, and an MS in Medical Science from Boston University in 2014. Outside of work, she is an avid baker and enjoys hiking and camping around the Northeast.

“You must strive to find your own voice because the longer you wait to begin, the less likely you are to find it at all.” – Robin Williams (Dead Poets Society)
Roxanne Murden
Roxanne Murden
Finance Manager
Roxanne Murden joined the ALS Therapy Development Institute in 2014. In her role as a Finance Manager, Roxanne, along with her team, take care of processing every donation that comes to the Institute. Roxanne attended Community College on the North Shore. As a single mom of 2 – Lara who is 17 and Aragorn who is 13 – she is kept very busy. Outside of the Insitute, Roxanne has been member of the School’s PTA for over 8 years and has help roles as both its President and Vice President. In her free time, Roxanne loves going to the beach, reading good books and baking.
Melissa Nollstadt
Melissa Nollstadt
Administrative Clinical Associate
Melissa Nollstadt joined the ALS Therapy Development Institute in 2018. Melissa is the clinical data coordinator for the Precision Medicine Program. After working in pre-clinical research for therapeutic devices in biotech, she was inspired by the impressive research efforts underway at the ALS Therapy Development Institute and the impact they have had on the lives of patients and their families. Melissa studied public health sciences at the University of Massachusetts in Amherst, and went on to work as a research associate with a growing startup in Cambridge. In her free time, she enjoys reading, baking, and snowboarding.

“We are part of this universe; we are in this universe, but perhaps more important than both of those facts, is that the universe is in us.” – Neil deGrasse Tyson
Chelsea Owens
Chelsea Owens
Director of Events
Chelsea Owens joined the ALS Therapy Development Institute in 2018. In her role as Director of Events, Chelsea works with a team of event, production and communications specialists on sponsorship, logistics, marketing, production, digital promotion, volunteer/committee recruitment and engagement across all events in support of ALS TDI. Previously, Chelsea worked with JDRF New York City Chapter on the Signature Events team and worked for a time Off-Broadway in Manhattan as a Stage Manager. She graduated from Columbus State University with a BFA in Theatrical Design & Technology, and was born and raised in Atlanta, Georgia.

“I hope you live a life you’re proud of. And if you find that you are not, I hope you have the strength to start all over again.”
Steve Perrin, Ph.D.
Steve Perrin, Ph.D.
President, Chief Executive Officer and Vice Chairman
Dr. Steven Perrin joined the ALS Therapy Development in 2007 as part of historical collaboration between the Institute, the Muscular Dystrophy Association and Augie's Quest with the goal of developing a center of excellence for ALS drug development and translational research for neurodegenerative diseases. Steven is currently the Chief Executive Officer and Chief Scientific Officer. He earned his Ph.D. at Boston University Medical Center in the Department of Biochemistry. Steven moved into the pharmaceutical industry in 1997 holding positions at the Hoechst-Ariad, Genomics Center, Aventis Pharmaceuticals and more recently as Director of Molecular Profiling at Biogen Idec. Since joining the Institute, Steven has spearheaded the architectural design and execution of the world’s largest Precision Medicine Program. This innovative program has bridged the gap between early preclinical target discovery and the advancement of biomarkers and quantitative outcome measures for clinical development in ALS and other neurological disease indications. Under his leadership ALS TDI has assembled a world class scientific team that in the last seven years has brought two potential treatments into clinical development for ALS. He has accomplished these objectives by creating innovative business models bridging philanthropic investments in early stages of drug development with for virtual for profit biotechnology companies to manage clinical translation. Steven is a frequent invited participant and speaker in international conferences on computational biology, genomics, drug development, and neurodegeneration.
Alan Premasiri
Alan Premasiri
Associate Scientist II
Alan Premasiri joined the ALS Therapy Development Institute in 2013. Alan graduated from Boston University with a degree in Neurobiology, and is applying to medical school. At the Institute, he does anything and everything related to the ALS-associated gene C9orf72. Alan is driven to work at the ALS Therapy Development Institute not only for his love of research, but also getting to meet inspiring people living with ALS and their families. Alan has ridden in the Tri-State Trek for two years alongside the ALS community. In his free time, Alan loves music, playing guitar, Ultimate Frisbee, tennis and anything science-related.

"Do or do not, there is no try" -Yoda
Clare Reich
Clare Reich
Development Director
Clare Reich joined the ALS Therapy Development Institute in 2011. She is the Lead Data Management Analyst and lives in Oakland, CA. Clare works at the Institute with the hope of helping to save her brother and all people with ALS. Her brother, Corey, was diagnosed with ALS in 2007. Since his diagnosis, Clare and her family have been dedicated to raising funds for the Institute. Clare graduated from Colby College in May 2011 with a degree in history and was the captain of the women’s volleyball team. Clare enjoys traveling, reading, watching sports, and spending time with her family.
“Life is too short to be anything but happy.” – Corey Reich
Carolyn Rodgers
Carolyn Rodgers
Design Manager
Carolyn Rodgers joined the ALS Therapy Development Institute in 2017. As the design and production specialist she designs visual content within the marketing and communications team. After collaborating with underfunded communities, Carolyn entered the nonprofit space to continue her dedication to bringing innovative visual communications to deserving causes. Carolyn has worked within a small tech startup, a university marketing office, and advertising agencies. She graduated from the University of Michigan with a BFA in Art & Design where she received awards in achievement in the area of disability, creative process, and leadership. Some of Carolyn's favorite things are painting colors and words, cooking brunch on the weekends, reading pretty books, and watching The Dick Van Dyke Show.

"Solving any problem is more important than being right." - Milton Glaser
Ricky Sanchez
Ricky Sanchez
Senior Associate Scientist
Ricardo (Ricky) Sanchez joined the ALS Therapy Development Institute in 2006 bringing more than twenty-nine years of experience in research and industrial histopathology to the team. Previously, he spent five years at Biogen Idec, Inc. as a histopathology supervisor. He also has over twenty years in research experience in nerve regeneration, inflammatory diseases, and cancer biology while working at Curis, and M.D. Anderson Cancer Center. Ricky received his BS in Biology and Histotechnology from Kean University of New Jersey. He and his family live in Andover, MA.
"Together in the fight to end ALS”.
Erin Stevens
Erin Stevens
Development Manager
Erin Stevens joined the ALS Therapy Development Institute in 2018. As a Development Manager, she spends her days partnering with families and individuals that are connected to the ALS Community with the same mission in supporting research and drug development ALS TDI. After volunteering at Tri-State Trek, Old Time Baseball, and participating in Corntoss, she was excited to join the Development Team within an organization she felt was vital to the future of ALS. Erin comes from a background of teaching a Middle & High School Math as well as working in operations for City Parks & Rec Departments and Chambers of Commerce. She is a graduate of the University of Florida with a Bachelor’s Degree in Hospitality. Erin enjoys travelling, playing sports, and spending time with friends and family.

“Alone we can do so little, together we can do so much.”
Shawn M. Sullivan
Shawn M. Sullivan
Lead Application Developer
Shawn Sullivan joined the ALS Therapy Development Institute in 2006 to help build web applications and the web presence for the Institute and many of its fundraising efforts. Specifically, Shawn is working to expand the web functionality of the Institute's drug discovery pipeline, the process database system we use to identify, evaluate, select and rank candidate drugs for testing. Shawn is also the lead developer for the Precision Medicine Program web portal which participants use to interact with their data. Shawn spent five years as a software developer at IMN Inc., where he helped clients such as Cisco Systems, Progress Software and Parametric Technology develop custom newsletters. He also has experience building Android apps, and in QA (quality assurance). Shawn attended Wentworth Institute of Technology.
Valerie Tassinari
Valerie Tassinari
Associate Scientist II
Valerie Tassinari joined the ALS Therapy Development Institute in 2010. She came to Boston in 2009, earned her BA in Marine Science from Boston University in 2012, and now is a member of the in vivo team at the Institute. Her responsibilities include validating gene expression endpoints in drug studies and quantitative gene copy number analyses to facilitate high quality and interpretable in vivo target discovery and pharmacology studies.
“Keep moving forward.” – Walt Disney
Ken Thompson
Ken Thompson
Director of Lab Operations
Ken Thompson joined the ALS Therapy Development Institute in 2000. A close friend of ALS patient Stephen Heywood, Ken discontinued his work in marine biology at the University of Alaska in 2000 to join ALS-TDI as a formulations scientist supporting the pharmacology team. At this time the lab was two small rooms in the depths of the New England Medical Center and the science team was six people strong.

In his unique role at ALS TDI, Ken supports the In vivo team, daily lab operations and serves as clerk for the board of directors.

Ken's previous research experience includes the molecular examination of starvation markers in larval stage cod at the University of Rhode Island. While at ALS TDI he has been coauthor on six publications.
Fernando Vieira
, M.D.
Fernando Vieira , M.D.
Chief Scientific Officer
Fernando G. Vieira, M.D. joined the ALS Therapy Development Institute in 2001. He is a research director focused on preclinical discovery and development of therapeutics for people with ALS. He works at the Institute because he believes it is the place where he can best work with others to help shape a world where an ALS diagnosis is no longer crippling. Fernando earned a bachelor’s degree in biological engineering from the University of Florida College of Engineering studied medicine at Harvard Medical School. He has dedicated his professional life to ending ALS. He has dedicated his personal life to being the best father he can be.
“The essential thing ‘in heaven and earth’ is, apparently, that there should be a long obedience in the same direction; there thereby results, and has always resulted in the long run, something which has made life worth living.” –Friedrich Nietzche
Ben Wakefield
Ben Wakefield
Lead Application Developer
Ben Wakefield joined the ALS Therapy Development Institute in 2009. Ben is responsible for maintaining existing web applications and implementing new web strategies. Previous to joining ALS TDI, Ben spent six years working in software and web development on an aerospace maintenance & engineering application. Prior to that, he worked for an information technology consulting firm in client/server based technologies. Ben is a graduate of the University of Maine.
Monica Wang
Monica Wang
Scientist I
Monica joined the ALS Therapy Development Institute in 2005. Formerly a member of Biogen's ALS discovery program, Monica has 28 years of basic research experience including stem cell research and animal surgeries in diabetes and Parkinson's disease. She spent five years focusing on HIV research at the New England Medical Center Hospital. She has extensive experience in the Cambridge biotechnology community, having held a senior position at Curis, where she filed successful patents. Monica is an expert in advanced confocal microscopy techniques, fluorescence, in-situ hybridization, immunohistochemistry, and cutting edge 3D histology using polymerized tissue sections. Her novel techniques include quantification of motor neurons, extraction of complex nerve assemblies, and imaging of ALS neuromuscular junctions. Monica loves to work out and is a CrossFit addict.
Yiding Yan
Yiding Yan
Associate Scientist III
Yiding joined ALS Therapy Development Institute in 2015. She has 20 years’ experience in bench research in both biopharmaceuticals and academics, where she was involved in a broad range of technology for in vitro research. Her previous experience focused on mouse genetics modeling of human disease, inflammation kinase assays, cancer biology cell-based assays, siRNA DMPK study and cell automation. Her specialties include cell assays development and gene construction. In her free time, Yiding enjoys practicing meditation and yoga.

Our Board

Augie Nieto, Chairman

Augie Nieto is the co-founder of Life Fitness, a global leader in the fitness industry. He was one of the original pioneers in the fitness industry and was president of Life Fitness for nearly 25 years until they were acquired by Brunswick Corporation in 1997.

Currently, Augie serves as an operating advisor to North Castle Partners, a private equity firm and is on the board of Curves, Jenny Craig, and Hydromassage. Augie formerly served on the board of Quest Software, where he was one of four members of its 'Special Committee' that negotiated the sale of Quest Software to Dell Computers in 2012. He also served on the board of Dynavox Systems, a developer of speech generating systems, and was Chairman of the Board of Octane Fitness.

Augie is Chairman of the Board of the ALS Therapy Development Institute in Cambridge, MA, the world’s largest ALS dedicated drug development organization. He is the Chief Inspirational Officer for Augie's Quest, an aggressive, cure-driven, international fundraising effort, having raised over $45 million to date to fund research at the ALS Therapy Development Institute.

Augie lives in Corona del Mar, California with his wife Lynne and dog Rubye. They have four adult, married children and seven grand babies.

Steven Perrin, Ph.D.
President, Chief Executive Officer, and Vice Chairman
Dr. Steven Perrin joined the ALS Therapy Development in 2007 as part of historical collaboration between the Institute, the Muscular Dystrophy Association and Augie's Quest with the goal of developing a center of excellence for ALS drug development and translational research for neurodegenerative diseases. Steven is currently the Chief Executive Officer and Chief Scientific Officer. He earned his Ph.D. at Boston University Medical Center in the Department of Biochemistry. Steven moved into the pharmaceutical industry in 1997 holding positions at the Hoechst-Ariad, Genomics Center, Aventis Pharmaceuticals and more recently as Director of Molecular Profiling at Biogen Idec. Since joining the Institute, Steven has spearheaded the architectural design and execution of the world's largest Precision Medicine Program. This innovative program has bridged the gap between early preclinical target discovery and the advancement of biomarkers and quantitative outcome measures for clinical development in ALS and other neurological disease indications. Under his leadership ALS TDI has assembled a world class scientific team that in the last seven years has brought two potential treatments into clinical development for ALS. He has accomplished these objectives by creating innovative business models bridging philanthropic investments in early stages of drug development with for virtual for profit biotechnology companies to manage clinical translation. Steven is a frequent invited participant and speaker in international conferences on computational biology, genomics, drug development, and neurodegeneration.
Stan Appel, M.D.
Dr. Appel is The Peggy and Gary Edwards Distinguished Endowed Chair for the Treatment and Research of ALS, Department of Neurology, Neurological Institute, The Methodist Hospital as well as a Professor of Neurology at Weill Medical College of Cornell University and a Professor of Biochemistry and Molecular Physiology at Baylor College of Medicine. He was previously Chair of the Department of Neurology at Baylor College of Medicine as well as Chief of Neurology and the James B. Duke Professor of Medicine at Duke University Medical Center. Dr. Appel is a native of Massachusetts and received his Bachelor Degree at Harvard University and his Medical Degree from Columbia College of Physicians and Surgeons. He is the Director of the MDA/ALS Research and Clinical Center at the Methodist Neurological Institute, and past Director of the National Institute of Aging Alzheimer's Disease Research Center. He has received a number of awards for his accomplishments in Neurology and Biochemistry, including the Gold Medal Award in 1997 from Columbia College of Physicians and Surgeons; the Sheila Essey Award in 2003 from the American Academy of Neurology, has been elected a Fellow of the American Association for the Advancement of Science in 2003, was awarded the Baylor College of Medicine Alumni Association's "Distinguished Faculty Award" in 2004, the MDA's Wings Over Wall Street Diamond Award in 2004, the Texas Neurological Society Lifetime Achievement Award in 2005 and the Forbes Norris Award for "compassion and love for humanity in research and treatment in patients with ALS" from the International Alliance of ALS/MND Associations in 2005.
Kent Bransford, M.D.
Kent's interest in ALS dates from the time of his brother-in-law, Augie Nieto's diagnosis. Kent received his Bachelor's degree in biochemistry from the University of California, Berkeley and his medical degree from Columbia University's College of Physicians and Surgeons. He completed his specialty training in internal medicine, hematology, and medical oncology at Cedars-Sinai Medical Center and USC's Norris Cancer Center in Los Angeles. Kent practiced clinical subspecialty medicine for nearly 30 years, and continues seeing patients pro-bono at the local free clinic. He served for over a decade on the board of directors of Physicians for Social Responsibility. In addition to his work on PSR's executive committee, he was national president in 2006. He currently lives on the Monterey Peninsula on California's central coast.
Alexander Cappello
The Chairman and CEO of the Cappello Group, Inc., a boutique merchant banking company. He has over twenty years experience in all aspects of corporate finance, investment banking, merchant banking and venture capital both in the U.S. and overseas. He has acquired control of and been the financial advisor to numerous public and private companies in transactions ranging from $10 million to $20 billion. Mr. Cappello is currently, or was previously, a member of the numerous boards of directors ranging from large corporations to academic and research institutes. The following is only a partial list of Mr. Cappello's board membership; YPO International, USC Board of Trustees, RAND Corporation, Inter-Tel (NASDAQ), Geothermal Resources International (AMEX; Chairman), CytRx Corporation (NASDAQ), Advanced Biotherapy, Inc. (OTC; Chairman), Australian Cancer Technology Limited (ASX – Sydney Australia), Catholic Big Brothers of Los Angeles (Chairman, 2002), Getty Institute and The Joffrey Foundation. Cappello received a Bachelor of Science degree, with honors, from the Marshall School of Business at the University of Southern California in 1977, including recognition as an "Order of the Palm" scholar. He was later awarded an Honorary Doctorate of Humanities from Goodwin College in Stanford, Connecticut. Mr. Cappello has been a guest lecturer at the USC, UCLA and Harvard Business Schools as well as numerous YPO, WPO, YEO and CEO International Universities. He has been quoted in the Wall Street Journal, BusinessWeek, FORBES, Dow Jones, the Los Angeles Times and the New York Times. He is also a contributing author to the recently published book, The New Investor Relations (Bloomberg PRESS). A California-native, Mr. Cappello has lived in Bakersfield, Los Angeles, New York, London and Geneva, Switzerland.
Eric Craven
Eric Craven has thirty years of professional experience with ten years in Engineering and twenty years in Human Resources – Compensation and Benefits. Eric began his career in Northrop Grumman's Engineering organization and is currently PepsiCo's Senior Vice President of Global Compensation and Benefits. Eric was diagnosed with ALS in April 2013 and has retired from PepsiCo to spend time with his family and to assist the TDI team in any way necessary to develop a cure. Eric received a Bachelor of Science, with honors, in Physics from UCLA, Masters of Science in Engineering Management from USC and an MBA from USC's Marshall School of Business. Eric's wife, Claire, is a graduate of LSU and formerly served as a Vice President of several national Advertising firms and currently partners along-side Eric in his work with TDI. Eric is a native of California and Claire of Louisiana, they currently reside in Connecticut with their three children David, Amanda and Elizabeth.
Jennifer Gore Dwyer

Jennifer Gore Dwyer is the owner of St. George Marine. The family-run company was established in 1986 by Jenny and her husband Pat. After her beloved husband passed away from ALS in June 2013, Jenny became sole owner and president of St. George Marine, working with her children Sean and Brenna to continue to run and grow the family business. The company owns two vessels. The F/V Jennifer A fishes crab in Alaska's Bering Sea, and in summer works with its sister ship, the F/V Brenna A, purchasing salmon on behalf of seafood processors in various parts of Alaska.

Jenny and Pat built their company from the ground up, working together on Alaska's fishing grounds and becoming involved in fisheries politics. Together, they lobbied state and federal officials on issues related to the Alaska seafood industry. In 2005, when Pat was diagnosed with ALS, the partnership built to lobby government on fish issues became a partnership working to live with ALS.

Through that partnership, Jenny became a committed advocate for the ALS cause. She started out with her local ALS chapter, raising over $100,000 to benefit PALS in the Pacific Northwest area. Jenny's involvement expanded to the national level. She and her family worked extensively behind the scenes in Washington, D.C. to ensure passage of the ALS Registry, which was signed into law by President George W. Bush in 2008. At the same time, recognizing the need for innovative research funding and federal funding, Jenny became a vocal supporter of ALS TDI. She established the first National YFALS Corntoss Tournament in Seattle. Jenny solicited sponsors, donors and participants from the family's significant network in the region. In 2013 the Seattle Corntoss event raised $55,000 for ALS drug development programs at ALS TDI.

On a national level, Jenny has made several trips to Capitol Hill in Washington, D.C. on behalf of ALS TDI. Jenny and ALS TDI met with ranking members of both the U.S. House and Senate to bring attention to the need for increased federal support for ALS translational drug research. Jenny reached out on the national level for all families living with ALS, including those of the military, who are diagnosed with ALS at a rate twice that of other individuals. In February of 2013, Jenny's advocacy went to the White House. She wrote directly to President Obama outlining the dismal statistics and the lack of research funding for this insidious disease. Her letter was so compelling that it made its way to President Obama's desk, and the President sent a hand written note to her and Pat. The president said he would look for ways to support "ALS specifically." Jenny is determined to continue reaching out to Washington, D.C. and the White House on behalf of ALS TDI, to ensure there is recognition and continued translational research funding for ALS, before more families are confronted with the life decisions that face all people with ALS.

Steve Fowler, Board Member Emeritus
Steve was diagnosed with ALS in 1997. An accomplished musician and composer, he was, at the time of his diagnosis, orchestrating and playing music for major motion pictures including The Lion King, A League of Their Own, Face Off, The Mask, and many others. He has served as musical director for the Grammy winning Brian Setzer Orchestra, published two ballets, many jazz tunes, a book of flute music, and his original poetry. Within months of his diagnosis with ALS, Steve became unable to play the flute and saxophone, but has started his third solo CD in collaboration with his younger brother, Ed. Without the ability for musical expression, Steve has redirected his creative energies toward studying and theorizing around the etiology of ALS. Steve has been a key activist and powerful advocate for patients becoming involved in the research and development of concrete therapies to treat ALS.
James Allen Heywood
Faced with his 29 year old brother Stephen's diagnosis of ALS in 1998, Jamie founded ALS TDI, the world's first nonprofit biotechnology company, and applied his engineering and management skills to dramatically accelerate ALS research. ALS TDI broke new ground on many fronts and has become widely recognized as one of the most promising and innovative research organizations. Under Jamie's leadership, ALS TDI implemented an industrialized therapeutic validation process and built one of the world's leading ALS drug discovery programs. ALS TDI was the first organization to run an open research program, posting in real time the results of its studies for patients, doctors, and the research community. It also pioneered a new model for engaging patients and families in fundraising and actively involving them in ALS research. Over 100 families have joined with Jamie, Stephen and the Heywood's to fund these innovative efforts. ALS TDI has raised tens of millions of dollars through its philanthropic, corporate, and government programs, culminating in the historic discovery partnership in 2007 with Augie's Quest and the Muscular Dystrophy Association. Jamie is the Chairman and co-founder of PatientsLikeMe the worlds leading patient information website with in depth information on treatments, symptoms, and real world information on managing life changing diseases. An MIT Engineer, he is an active investor and advisor to startups, companies and non profits working improve the way in which biomedical research is conducted. Jamie's work has been profiled in the New Yorker, 60 Minutes, Pulitzer Prize winner Jonathan Wiener's book, His Brothers Keeper, and in the Sundance award winning documentary So Much So Fast.
John Heywood, Ph.D., Sc.D.
John is the Sun Jae Professor of Mechanical Engineering and Director of the Sloan Automotive Lab at MIT. He has made major contributions to the fields of transportation, energy and air pollution, and consults to both industry and the government on technical and policy issues. His book, Internal Engine Fundamentals, is regarded as the definitive work in the field. He was elected to the National Academy of Engineering in 1998, and the American Academy of Arts and Sciences. Professor Heywood has an honorary Doctor of Technology degree from Chalmers University of Technology in Sweden, and an honorary Doctor of Science degree from City University in London.
Spiros Jamas, Sc.D.
Spiros Jamas was the President and CEO and co-founder of Tempero Pharmaceuticals, a GSK-funded company focusing on T-cell mediated diseases. Prior to joining Tempero, Dr. Jamas was the Global Healthcare Analyst for State Street Global Advisors (SSGA), a global institutional asset management firm. Dr. Jamas has over 20 years senior management experience in the biopharmaceutical industry serving as CEO and/or founder of several biotech companies (Tempero, Enanta Pharmaceuticals, Alpha-Beta Technology, Inc.). In these capacities he was responsible for raising over $280M in funding through venture capital, public and debt offerings and led R&D programs from discovery research to advanced clinical development. Dr. Jamas obtained a Doctor of Science in Biotechnology from M.I.T. in 1987, a M.Sc. also from M.I.T. in 1983 and a B.Sc. in Chemical Engineering from UMIST, England.
Keith P. Melanson, Governance & Nominating Committee Chair
Keith is Managing Director - Investment Officer at a Financial Institution working with high-net worth families and fixed income portfolios. Previously, Mr. Melanson held similar positions at Credit Suisse, Private Banking USA and J.P. Morgan where he managed fixed income portfolios for banks and insurance companies and covered corporate cash portfolios for several fortune 500 companies. Earlier, he worked at Griffin, Kubik, Stephens & Thompson Investment Bank. Mr. Melanson graduated with a BS in Finance and Investments from Babson College. Keith's brother, Ken Melanson, passed from ALS in 2004. Keith first became involved with ALS TDI in 2001 and currently serves as Chair of the Governance & Nominating Committee of the Board of Directors.
Leslie Michelson
Leslie brings strong leadership and more than 20 years of healthcare experience. Mr. Michelson has served as a founder, CEO, investor, advisor and/or director for a portfolio of entrepreneurial healthcare, technology and real estate companies. After practicing law in Washington, D.C., Leslie served as Special Assistant to the General Counsel of the U.S. Department of Health and Human Services during the Carter Administration. He then joined a private equity investment firm focused on healthcare and real estate investments. In 1988, he founded and became Chairman and CEO of Value Health Services, one of the first and most profitable disease management companies. He was the co-founder and Chairman, and co-CEO of Protocare, a provider of clinical trial site and disease management services to the biotechnology and pharmaceutical industries. In 1999, Mr. Michelson co-founded and served as CEO of Acurian, which recruits patients and physicians for clinical trials. Mr. Michelson serves on the Board of Directors, and is the Audit Committee Chair, of Catellus, a $3 billion NYSE industrial REIT and is a member of the Board of Directors for Nastech, a NASDAQ-traded biotechnology company focused on innovative drug discovery technology. Mr. Michelson received a B.A. from the John Hopkins University and a J.D. from Yale Law School. He and his wife, Beth, have two daughters and reside in Los Angeles. Leslie is the Vice Chairman of the Board of Directors and serves as Chair of the Audit Committee at ALS TDI.
Andrew Niblock

Andrew Niblock is the Director of Schoolwide Initiatives and the former Head of Lower School at the Greenwich Country Day School, Greenwich, CT. Prior to his current position he was the Director of Lower School at Hamden Hall Country Day School and spent eleven years as a teacher, coach and administrator at Isidore Newman School in New Orleans.

In July 2016 Andrew was diagnosed with ALS. In the time since, Andrew and his family have become more hopeful, not less. Andrew's life's work is education, and this is the lens through which he views ALS.

There has never been a more exciting time in ALS science. The creativity that comes with looking at problems from different angles, collaboratively, and with unprecedented advances in technology, gives justified cause for hope.The avalanche of ideas in the scientific world of this fight calls for commensurate creativity in the world of support.

Lynne Nieto

After graduating from University of Colorado with a BA in Accounting, Lynne joined her family real estate development and management firm in 1980. Her original involvement was with the single family home building division of the business, building upwards of 200 homes per year. She later became president of 'Classic Management' – the company's property management division, and grew its portfolio of apartments from 800 to 1,200 units, while also overseeing the commercial and office building portfolio. She retired from the firm in 2000.

Lynne continues to be involved in real estate investing and served on the board of CT Realty, a California real estate investment company. She served as Co-Chair of the ALS Division of the Muscular Dystrophy Association from 2006 until "Augie's Quest" left the ranks of MDA and became part of ALS Therapy Development Institute in 2014.

Lynne co founded Augie's Quest with her husband Augie and has played a pivotal role in its success through her vision, leadership and focus on the bottom line where her accounting background has been key. Among other things, Lynne created the concept for the BASH fundraiser, Augie's Quests most successful single day event, and she represents Augie as the "voice of Augie's Quest", at all major events and with the media.

Lynne lives in Corona del Mar, California with her husband, Augie, and dog, Rubye. They have four adult, married children and five grand babies.

Theodore Reich, Treasurer and Audit Committee Chair
ALS TDI's first contact with Ted and his wife, Wendy, was at a San Francisco ALS 101 in October of 2007. The Reich's attended the seminar because their 22 year old son, Corey, who was enrolled at Middlebury College, had recently been diagnosed with ALS. Ted has been a CPA for the past 25+ years in the Bay Area. He formerly worked for Arthur Anderson, and has held his own firm for the past twenty years. Ted is very well connected in many California industries such as logging, farming, grocery chains, and dozens of other industries that his firm supports. In the last three months of 2007 ALS TDI received $43K via the Reich network. In April of 2008 Wendy and Corey visited the lab in Cambridge. In August 2008, with Mike Shannon's coaching, the Reich family generated almost $400K through their first fundraising event (Corey's Crusade). In November of 2008 Corey and Wendy attend the 2008 ALS TDI Leadership Summit. Ted, Wendy, and Jacque Portewig (Wendy's Sister) are ALS TDI Ambassadors. In January of 2009 Ted joined the new ALS TDI Advisory Council. Corey himself is now interested in taking a more active role as a patient-advocate and may be willing to do some public speaking to benefit ALS TDI's outreach. In fact, Corey has joined together with several other young people living with ALS to create the ''Young Faces of ALS'' campaign in 2010 and attended several MLB games to raise awareness of ALS and dollars for research. This year, the Young Faces of ALS campaign launched its first national fundraising initiative, a National Cornhole Challenge Day, which took place on June 18, 2011 and raised $150,000. In addition to fundraising, Ted has provided support via pro bono legal services through one of his many contacts, Darin DeAngeli with Ahrens & DeAngeli in Seattle and Boise. In total, the Reich network has generated just over $1.6 million for research at ALS TDI!
Rob Rodin, Executive Compensation Committee Chair
Bio="Rob is the Chairman and CEO of RDN Group; strategic advisors focused on corporate transitions, customer interface, sales and marketing, distribution and supply chain management. (Customers include: GM, GE, US Navy, Avnet, Siemens, Simon and Schuster). Additionally, he serves as Vice Chairman, Executive Director and Chairman of the Investment Committee of CommerceNet which researches and funds open platform, interoperable business services to advance commerce. Mr. Rodin served for over 10 years as CEO and President of Marshall Industries (NYSE: MI) a global, industrial, electronics distributor and supply chain management company with over $2 billion in sales. Information Week Magazine highlighted Marshall Industries as the "World's Number One Company in the Use of Technology", and CIO Magazine recognized Mr. Rodin as one of the "Top 100 Leaders for the New Millennium". UCLA presented Mr. Rodin with the "Information Systems Award for System Leadership" and the University of Connecticut presented him with the "Distinguished Alumni Award" and elected him to the "University Hall of Fame". Mr. Rodin's best selling book, "Free, Perfect and Now: Connecting to the Three Insatiable Customer Demands", chronicles the radical transformation of Marshall Industries. The changes he led have been taught as case studies at Harvard Business School, Columbia University, USC, MIT, and Stanford University. Mr. Rodin's Board activities include: the Board of Directors of Napster (NAPS)(formally Roxio) as Chairman of the Compensation Committee and a Member of the Audit Committee, Vice Chairman of the Board of Directors of CommerceNet, Board Member / Director of supplyFX, Board Member /Director and Member of the Governance and Nominating Committee of SM&A (NASDQ: WINS), Director of Inter-tel (NASDAQ: INTL), Advisory Board of LASEC (Los Angeles Sports and Entertainment Commission) Advisory Board of Electronics Supply & Manufacturing Magazine (CMP Publications), on the planning committee for Harvard and Stanford Presidents Seminars (YPO) and on University of Connecticut's School of Business Board of Advisors (Executive Council and Strategic Development Committee) as well as several private company advisory boards. Mr. Rodin formerly served on the Advisory Board of Distribution at USC, the Board of Directors of RosettaNet, as a Trustee of the W. Edwards Deming Institute, and President of NEDA's (National Electronic Distribution Association) Education Foundation. Rob is the Chair of the Executive Compensation Committee of the Board of Directors at ALS TDI.
Paul A. Sallaberry

Paul Sallaberry is a software industry veteran with a career encompassing the build and operational management of Enterprise-class worldwide sales, marketing, technology and consultative services organizations.

As Executive Vice President of Worldwide Field Operations for VERITAS Software, Paul was responsible for defining strategy, managing operational activity driving revenue in excess of $1.65 billion, and achieving profit goals for the corporation's global multi-tier sales distribution and professional services operations. Paul propelled the organization's transition from that of an emerging start-up to its unprecedented position as the world's leading provider of enterprise storage management solutions, and industry-recognized sales distribution powerhouse. Paul concluded his tenure with VERITAS in December of 2003 in the capacity of Executive Vice President of Sales Strategy, having successfully positioned the organization's International growth territories for the next phase of sales expansion.

Paul joined VERITAS in the role of Senior Vice President of Worldwide Field Operations, in April 1997, from OpenVision Technologies, Inc., a leading provider of client/server systems software for automated operations, application availability, backup, and network security. In this capacity, Paul successfully led the integration of OpenVision's customer-facing functions with those of VERITAS, and laid the field operations foundation which subsequently enabled VERITAS' future worldwide distribution expansion. In 1999, Paul led the seamless worldwide integration of VERITAS' acquisition of Seagate, growing VERITAS' worldwide quota-carry sales capacity from an employee base of 200 at acquisition, to its ultimate capacity of 2600+. Through this evolution, Paul successfully charted the course for VERITAS' high-growth in sales productivity through a channel expansion strategy leveraging direct account management, channel partnerships, e-business readiness, mergers and acquisitions, and value-add services including consulting and end-user education.

While at OpenVision, Paul served in the capacity of Senior Vice President of Sales, where he led the organization's product and professional services revenue growth through IPO, and its subsequent acquisition. Prior to OpenVision, Paul held a series of positions at Oracle Corporation from 1989 through 1992, including Vice President of Oracle's Vertical Sales Division, a capacity in which Paul defined Oracle's vertical sales strategy, and evolved the organization from an emerging market opportunity to that of a major component of Oracle's mainstream revenue.

He serves on the Board of Directors for Acquia, Calypso Technologies, Moovweb, Quorum Labs, Dataguise, Livemagic, and is Chairman of the Board of Seal Software. He also advises several young Silicon Valley companies. He is a member of the U.C. Davis Foundation Board of Trustees; serves on the Deans Advisory Council for the Graduate School of Management., and Is a member of the Sacred Heart Schools Board of Trustees Additionally, he is a frequent speaker at the Stanford Graduate School of Business and the UCLA Anderson School of Management. Paul holds a Bachelor of Science degree from the University of California, Davis.

Robert Sepucha
Robert Sepucha is Senior Vice President, Policy and Business Development for Fresenius Medical Care North America, the nation's largest integrated provider of clinical services and products for persons undergoing treatment for kidney failure, including chronic renal dialysis. Prior to joining Fresenius, Robert served as general counsel for the Massachusetts Life Science Center, as well as chief of staff and senior policy advisor to Congressman Harold Ford, Jr. (D-TN), where he was the Congressman's primary advisor on legislative strategy, political activities, media strategy and legal issues. Robert also practiced law for nearly a decade at Sonnenschein Nath & Rosenthal and Gunderson Dettmer, where he represented venture capitalists and emerging growth technology companies across the country. Robert received a J.D. from the University of Michigan and a B.S. in government and economics from Dartmouth College.
Michael M. Smith
Michael M. Smith is president of B.T. Loftus Ranches, Inc., a family-owned farming and orchard operation in Washington's Yakima Valley. He is also founder, director and former president of Yakima Chief, Inc., an international hops sales organization. Smith and his wife, Cheryl Hanses Smith, have been supporters of ALS-focused organizations for many years, funding both patient services and research efforts. The Hanses family has the inherited form of ALS, and there are three family members currently battling the disease. Recently, they worked with ALS TDI to develop the "Ales for ALS" program, a unique craft brewery-based fundraising initiative created to fund drug development at ALS TDI.
Julie Swan

Julie Swan spent almost her entire 34-year professional career in the foodservice industry, retiring from Sysco Corporation, as a corporate vice president of finance in June 2012. She worked in various financial roles, both in the operating divisions as well as at the corporate office in Houston, Texas. Asked to help establish Sysco's Strategic Management department in 2012, she relocated from Miami to Houston. While there she worked extensively with Sysco's non-traditional foodservice divisions, including produce and meat companies as well as its international acquisitions.

As she approached retirement, her son Kevin was diagnosed with ALS in February of 2012. Within six weeks of diagnosis, Kevin created A Life Story Foundation to raise awareness and create action to find treatments and ultimately, a cure for ALS. Julie assumed the role of Chief Financial Officer at A Life Story Foundation, a position she still holds currently. Since it's inception, A Life Story Foundation has raised over $500,000 and has partnered with ALS TDI as its research partner.

Julie has been involved with not for profit organizations throughout her career. She has served on the corporate boards of the United Way, YMCA, Boys and Girls Clubs of Manatee County and Broward County, as well as being Treasurer of the Women's Foodservice Forum.

Julie has a BS degree from Georgetown University and MBA from Nova University. She is married and has two sons and lives in Bradenton, Florida.